Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial
 
  • Details

The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial

Journal
Journal of Microbiology, Immunology and Infection
Journal Volume
52
Journal Issue
5
Pages
685-692
Date Issued
2019
Author(s)
ARISTINE CHENG  
SZU-MIN HSIEH  
SUNG-CHING PAN  
Li Y.-H.
Hsieh E.-F.
Lee H.-C.
Lin T.-W.
Lai K.-L.
Chen C.
Shi-Chung Chang S.
SHAN-CHWEN CHANG  
DOI
10.1016/j.jmii.2019.03.009
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068005054&doi=10.1016%2fj.jmii.2019.03.009&partnerID=40&md5=42881fcba96b4ffce0fd578f2e803d01
https://scholars.lib.ntu.edu.tw/handle/123456789/515763
Abstract
Background: Development of an efficacious egg-free mock-up H5N1 vaccine is key to our preparedness against pandemic avian flu. Methods: This is a single-center, randomized, observer-blinded phase I clinical trial evaluating the safety and immunogenicity of an alum-adjuvanted Madin–Darby canine kidney (MDCK)-derived inactivated whole-virion H5N1 influenza vaccine in healthy adults. Hemagglutination inhibition (HAI) and neutralizing antibody titers were measured using horse and turkey red blood cells (RBCs). Results: Thirty-six adult subjects were randomized to receive two doses of 0.5 mL of the MDCK-derived H5N1 alum-adjuvanted vaccine containing 7.5, 15, or 30 μg of hemagglutinin (HA) 21 days apart. The candidate vaccine was well tolerated and safe across the three dosing groups. The most frequent adverse event was injection site pain (46.5%). Both HAI and neutralizing antibody titers increased after each vaccination in all three dosing groups. The best HAI responses, namely a seroconversion rate of 91.7% and a geometric mean ratio of 9.51 were achieved with the HA dose of 30 μg assayed using horse RBCs at day 42. HAI titers against H5N1 avian influenza virus was significantly higher when measured using horse RBCs compared with turkey RBCs. Conclusions: This Phase I trial showed the MDCK-derived H5N1 candidate vaccine is safe and immunogenic. The source of RBCs has a significant impact on the measurement of HAI titers (ClinicalTrials.gov number: NCT01675284.). ? 2019
SDGs

[SDGs]SDG3

Other Subjects
aluminum potassium sulfate; influenza vaccine; Influenza virus hemagglutinin; neutralizing antibody; aluminum derivative; hemagglutinin, avian influenza A virus; immunological adjuvant; inactivated vaccine; influenza vaccine; neutralizing antibody; virus antibody; adult; animal cell; antibody response; antibody titer; arthralgia; Article; controlled study; coughing; dermatitis; drug safety; drug tolerability; dysmenorrhea; erythrocyte; fatigue; female; headache; hemagglutination inhibition; horse; human; human experiment; Influenza A virus (H5N1); injection site bleeding; injection site erythema; injection site pain; injection site pruritus; injection site reaction; injection site swelling; male; MDCK cell line; middle aged; myalgia; nonhuman; open study; phase 1 clinical trial; prospective study; randomized controlled trial; rigor; seroconversion; single blind procedure; turkey (bird); vaccine immunogenicity; young adult; adverse drug reaction; adverse event; animal; avian influenza; bird; blood; clinical trial; dog; hemagglutination inhibition test; immunology; influenza; intramuscular drug administration; pandemic; pathophysiology; safety; Taiwan; vaccination; Adjuvants, Immunologic; Adult; Aluminum Compounds; Animals; Antibodies, Neutralizing; Antibodies, Viral; Birds; Dogs; Drug-Related Side Effects and Adverse Reactions; Female; Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins, Influenza Virus; Horses; Humans; Immunogenicity, Vaccine; Influenza A Virus, H5N1 Subtype; Influenza in Birds; Influenza Vaccines; Influenza, Human; Injections, Intramuscular; Madin Darby Canine Kidney Cells; Male; Middle Aged; Pandemics; Safety; Seroconversion; Taiwan; Vaccination; Vaccines, Inactivated; Young Adult
Publisher
Elsevier Ltd
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science